Literature DB >> 8946818

Tumor-specific autologous cytotoxic T lymphocytes from tissue sections.

S Q Liu, H Shiraiwa, K Kawai, H Hayashi, H Akaza, B S Kim, A Oki, M Nishida, T Kubo, K Hashizaki, K Saijo, T Ohno.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8946818     DOI： 10.1038/nm1296-1283

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  Tumor vaccine against recurrence of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jiang Liang; Qiang He; Ming Kuang; Jia-Ming Lia; Ming-De Lu; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.

Authors:  Hideo Tsurushima; Yoshihiko Yoshii; Kam W Leong; Tadao Ohno
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Expansion of human autologous cytotoxic T lymphocytes on fixed target tumor cells.

Authors:  K Horiuchi; H Tsurushima; B Soo Kim; S Qin Liu; K Saijo; Y Saijo; T Nukiwa; N Nomura; M Matsumura; T Ohno
Journal:  Cytotechnology       Date:  1998-03       Impact factor: 2.058

Review 4.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

5.  Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes.

Authors:  K Kawai; K Saijo; T Oikawa; Y Morishita; M Noguchi; T Ohno; H Akaza
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

6.  Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids.

Authors:  K Kawai; H Hayashi; Y Ozaki; K Saijo; S Q Liu; H Akaza; T Ohno
Journal:  Cytotechnology       Date:  2001-09       Impact factor: 2.058

7.  Long-term survivor of relapsed MFH on the thigh treated with autologous formalin-fixed tumor vaccine (AFTV) combined with limb-sparing surgery and radiotherapy.

Authors:  Takeshi Todoroki; Tadashi Kondo; Shinji Sugahara; Yukio Morishita; Kensaku Mori; Tadao Ohno
Journal:  World J Surg Oncol       Date:  2011-08-24       Impact factor: 2.754

Review 8.  Immunotherapeutic advancements for glioblastoma.

Authors:  Leonel Ampie; Eric C Woolf; Christopher Dardis
Journal:  Front Oncol       Date:  2015-01-29       Impact factor: 6.244

9.  Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma.

Authors:  Bao Gang Peng; Shu Qin Liu; Ming Kuang; Qiang He; Saeri Totsuka; Lan Huang; Jiefu Huang; Ming-De Lu; Li-Jiang Liang; Kam W Leong; Tadao Ohno
Journal:  Jpn J Cancer Res       Date:  2002-04

10.  Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine.

Authors:  Jui-Tung Chen; Tadao Ohno
Journal:  Clin Case Rep       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.